Gepirone: A Current Breakthrough to Antidepressant Outgrowth
Year: 2025
Type: article
Abstract: Major depressive disorder (MDD) has been a persistent challenge in the field of mental health. Several drugs in past have been used to treat mental illness with noticeable emotional depression. Gepirone is a promising medication for patients combating with MDD. FDA approved gepirone in September 28, 2023 under brand name Exxua as a novel antidepressant drug to be a possible substitute to selective serotonin reuptake inhibitors (SSRIs). Gepirone does not belong to selective serotonin reuptake inhibitors (SSRI), however it still works by activating certain serotonin receptors. Gepirone ER (Exxua) is an efficacious medication in the treatment of mental health of patients. Exxua is to be used with cautious as it can cause QT prolongation resulting in arrhythmias which may be life threatening. The drug poses new vision to other treatment options available in market. The significant stage in development of the drug will assist researchers, physicians and regulatory bodies to be aware of the challenges pertaining to mental health and improving treatment options. The present review presents critical view on gepirone (Exxua) to pharmacists and physicians as a new treatment option of mental illness.
Author: Nida Alam1, Vivek Kumar2, Najmussehar3, Nadeem Siddiqui4*
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W6930650266
FWCI:
Cites:
Cited by:
Related to: